ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

OVID Ovid Therapeutics Inc

0,8463
0,0567 (7,18%)
Dernière mise à jour : 17:50:08
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Ovid Therapeutics Inc OVID NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
0,0567 7,18% 0,8463 17:50:08
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,7596 0,7452 0,8684 0,7896
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
17/6/202413:10EDGAR2Form 8-K - Current report
17/6/202412:55GLOBEOvid Therapeutics Reports on Takeda’s Announcement of Phase..
07/6/202422:22EDGAR2Form 8-K - Current report
14/5/202423:19EDGAR2Form S-8 - Securities to be offered to employees in employee..
14/5/202414:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/5/202414:03EDGAR2Form 8-K - Current report
14/5/202414:00GLOBEOvid Therapeutics Reports Business Updates and First Quarter..
13/5/202413:00GLOBEOvid Therapeutics to Present at the H.C. Wainwright 2nd..
04/4/202414:00GLOBEOvid Therapeutics to Present at the 23rd Annual Needham..
08/3/202414:24EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
08/3/202414:20EDGAR2Form 8-K - Current report
08/3/202414:00GLOBEOvid Therapeutics Reports Business Updates, Fourth Quarter..
28/2/202414:00GLOBEOvid Therapeutics to Present at the TD Cowen 44th Annual..
27/2/202400:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202423:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202423:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202417:10EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202412:06EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202414:00GLOBEOvid Therapeutics to Present at the Oppenheimer 34th Annual..
06/12/202323:08EDGAR2Form 8-K - Current report
01/12/202313:30GLOBEOvid Therapeutics to Present Five Abstracts Supporting its..
16/11/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
15/11/202322:11EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03/11/202321:08EDGAR2Form S-3 - Registration statement under Securities Act of..
03/11/202313:13EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202313:10EDGAR2Form 8-K - Current report
03/11/202313:00GLOBEOvid Therapeutics Reports Third Quarter 2023 Financial..
18/10/202314:04EDGAR2Form 8-K - Current report
18/10/202314:00GLOBEOvid Therapeutics and Ligand Pharmaceuticals Enter into a..
10/10/202314:00GLOBEOvid Therapeutics to Present at the Jefferies Biotech..
02/10/202318:15EDGAR2Form 8-K - Current report
26/9/202313:30GLOBEOvid Therapeutics to Host Investor Event - R&D Day on..
20/9/202313:30GLOBEOvid Therapeutics to Present at the 2023 Cantor Fitzgerald..
30/8/202314:00GLOBEOvid Therapeutics to Participate in Upcoming September..
04/8/202315:23EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
04/8/202315:10EDGAR2Form 8-K - Current report
04/8/202314:00GLOBEOvid Therapeutics Reports Second Quarter 2023 Financial..
01/8/202314:00GLOBEOvid Therapeutics to Present at the BTIG Virtual..
31/7/202323:21EDGAR2Form SC 13G - Statement of acquisition of beneficial..
28/6/202314:00GLOBEOvid Therapeutics Expands Its Scientific Leadership Team &..
26/6/202314:00GLOBEOvid Therapeutics Added to Russell 3000® Index